Premenstrual Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Type (Analgesics, Antidepressants, Oral Contraceptives and Ovarian Suppression Agents, Others), By Type (Prescription, OTC), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global premenstrual syndrome treatment market size was valued at USD 22.6 billion in 2022. It is estimated to reach USD 37.22 billion by 2031, growing at a CAGR of 5.7% during the forecast period (2023–2031). The expansion of the business is helped by programs that governments and non-governmental organizations are carrying out to improve the health of women and the educational possibilities that are accessible to them.

The phrase "premenstrual syndrome" (PMS) treatment refers to the therapeutic methods that are done to decrease the emotional, physical, and psychological symptoms that are linked with premenstrual syndrome (PMS) in women. These symptoms can include irritability, depression, and irritability during menstruation. These symptoms can include bloating, breast soreness, general body discomfort, fatigue, changes in mood, and anxiety. The symptoms of premenstrual syndrome, also known as PMS, generally manifest themselves at the end of the luteal phase and disappear either with the onset of menstruation or not long after it has begun.

The treatment approach may include hormonal contraceptives, antidepressants, analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), diuretics, and medicines that decrease ovarian function. Most of these medicines are available either "over the counter" (sometimes known as "OTC") or by way of a prescription from a qualified medical professional. Cannabidiol extracts are employed in manufacturing new drugs for treating PMS, including topical gels, lotions, pills, and suppositories, among other forms of medication. The management of mood imbalances, the alleviation of uterine cramps, and the promotion of muscular relaxation are all goals that can be accomplished with the help of these treatments.

Market Dynamics

Global Premenstrual Syndrome Treatment Market Drivers:

Rise in Prevalence of PMS

Premenstrual syndrome, sometimes known as PMS, is a hormonal condition that affects many women of childbearing age. It is projected that a rise in premenstrual syndrome (PMS) incidence will result in a rise in the demand for medications used to treat PMS. For instance, the American Psychiatric Association claims that almost all women of childbearing age experience premenstrual symptoms, yet only a tiny number of these women are diagnosed with premenstrual dysphoric disorder (PMDD). This is because PMDD is a relatively rare condition. It is anticipated that the prevalence of premenstrual syndrome will fuel the need for premenstrual syndrome treatment pharmaceuticals, which would, in turn, drive the premenstrual syndrome treatment market growth. As a result of this, the market will grow.

Growth In Awareness Regarding PMS Therapeutics

Premenstrual syndrome, also known as PMS, is increasingly negatively affecting modern women's lifestyles due to the changing demographics of the female population; premenstrual syndrome (PMS) is more common in younger women and represents a bigger risk to their overall health. The industry's rapid expansion can be attributed, in part, to the ease with which patients can now gain access to premenstrual syndrome (PMS) treatments and the broad availability of PMS therapy drugs. In addition, the expansion of the business is helped by programs that governments and non-governmental organizations are carrying out to improve the health of women and the educational possibilities that are accessible to them.

Global Premenstrual Syndrome Treatment Market Restraint:

Poor Demand in Underdeveloped Countries

Menstruation and the social standing of women are still associated with a large amount of social stigma in some parts of the world, particularly in rural and outlying areas, as well as in the Middle East and other less developed countries. This is especially the case in more rural parts of the country. In rural areas of the Middle East and Africa, there are a variety of cultural characteristics that influence both expectations and one's self-perception of the sickness. The social reasons largely to blame for the stigma attached to premenstrual syndrome (PMS) include patriarchal countries, societies that prevent free communication, and cultures in which women are less exposed to the outside world, the United States. Patients are consequently less inclined to seek therapy for the ailment as a consequence of this. Because of this, the market continues to decline, contributing to the overall economic crisis.

Global Premenstrual Syndrome Treatment Market Opportunities:

Higher Number of Unmet Needs for Treatment of PMS

There are many unmet requirements for the treatment of premenstrual syndrome (PMS). As a result of the fact that the now available off-label products are not effectively supplying the market, there are huge chances for new entrants to profit in the market. The treatment now focuses on relieving the condition's symptoms and has a low efficacy profile. As a result, the therapeutic choices that are currently available are unable to satisfy the requirements of the market. Additionally, there is a significant unmet need for treatments that directly target the underlying etiology and pathophysiology that are accountable for the development of PMS symptoms. As a result, the global market for treating PMS is waiting for new alternatives that are both more effective and safer to meet the now unmet needs. As a result, more unmet demands create an opportunity for new entrants to emerge by addressing the same needs.

Regional Analysis

Based on region, the global premenstrual syndrome treatment market share is bifurcated into North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the most significant global premenstrual syndrome treatment market shareholder and is estimated to exhibit a CAGR of 2.9% over the forecast period. The market for premenstrual syndrome treatment in North America, which currently accounts for the largest share of the global market, is expected to continue to grow, primarily as a result of the region's higher prevalence of PMS, increased healthcare awareness, well-developed healthcare infrastructure, early disease detection, availability of skilled medical personnel, and simple access to therapeutics. For instance, the American Psychiatric Association reports that premenstrual symptoms are experienced by roughly 90% of women of childbearing age.

Additionally, the market continues to expand in this region as a result of the presence of advanced healthcare facilities, increased public awareness of healthcare needs, widespread accessibility of PMS treatment therapeutics, rising demand for advanced healthcare services accompanied by higher healthcare spending, and the presence of numerous hospitals and diagnostic centers outfitted with advanced healthcare systems.

Europe is anticipated to exhibit a CAGR of 3.7% over the forecast period. Europe accounted for the second-largest market share for premenstrual syndrome treatments worldwide. During the projection period, the market for premenstrual syndrome treatments in European nations is expected to expand steadily. The main growth drivers in Europe are the rising prevalence of PMS, the rising demand for PMS medications, and the accessibility of these treatments.

Furthermore, a developed healthcare infrastructure, the availability of experts with the necessary training, a higher prevalence of PMS, and increased healthcare spending fuel the market's expansion in Europe. Due to the increased use of PMS medicines, increased hospitals and diagnostic facilities with qualified medical staff, and early PMS identification, Europe is the second largest stakeholder in the global premenstrual syndrome treatment market. Premenstrual syndrome treatment is expected to experience significant expansion in Germany, France, and the UK due to a sizable target population, a well-developed healthcare system, and the accessibility of medications.

In Asia-Pacific, the Premenstrual Syndrome treatment industry prospects are plentiful and are expected to increase fastest over the forecast period. The huge population base, increased PMS awareness, rising incidence of premenstrual syndrome treatment systems, and rising demand for PMS medicines all contribute to the market expansion in this area. Asia-Pacific contains nations that are still developing and consequently act as emerging markets. Improved health awareness, expanding healthcare infrastructure, increased hospitals and diagnostic centers with cutting-edge medical technology, and increased target population in emerging economies are the main drivers of market expansion.

In LAMEA, the premenstrual syndrome treatment industry is still in its infancy due to a lack of advanced healthcare facilities and a shortage of educated medical experts. The LAMEA region is a market that is still developing, which offers market participants the possibility of profitable expansion. This is due to several factors, including an increase in the number of people who fall into the target market, an increase in the number of hospitals, an improvement in the infrastructure of healthcare, and an increase in awareness toward the treatment of premenstrual syndrome.

Segmental Analysis

The global premenstrual syndrome treatment market is bifurcated into drug type, type, and distribution channel.

Based on the drug type, the global premenstrual syndrome treatment market is bifurcated into analgesics, antidepressants, oral contraceptives, ovarian suppression agents, and others. 

The Analgesics segment dominates the global market and is projected to exhibit a CAGR of 3.2% over the forecast period. Analgesic medications such as ibuprofen, acetaminophen, diclofenac, and naproxen are commonly used to treat the discomfort associated with premenstrual syndrome (PMS). According to several studies, for over-the-counter analgesic medicines to be effective in treating premenstrual syndrome (PMS) symptoms, they must be taken immediately before the onset of premenstrual pain or at regular intervals during the duration of the discomfort.

Analgesics are typically taken to alleviate the painful symptoms of premenstrual syndrome (PMS), which might include stomach cramps, headaches, muscular discomfort, and joint pain. These medications are accessible without a doctor's prescription and can be purchased over the counter; however, excessive usage may result in undesirable side effects. The preferential utilization of nonsteroidal anti-inflammatory medications (NSAIDs) in the management of premenstrual syndrome (PMS) is one of the key aspects that is majorly driving the market expansion of this segment. Other key drivers include the increased prevalence of PMS, a growing awareness linked to PMS, and easy accessibility to these pharmaceuticals.

Based on type, the global premenstrual syndrome treatment market is segmented into prescription and OTC. 

The OTC segment dominates the global market and is predicted to exhibit a CAGR of 3.3% during the forecast period. Over-the-counter medications, sometimes known as OTC drugs, can be purchased by consumers without requiring a prescription from a medical practitioner. When a medicine is sold over the counter (OTC), it must pass inspection by regulatory agencies to guarantee that its components are safe and effective when taken without a prescription from a doctor. In addition, over-the-counter (OTC) drugs are controlled based on their active pharmaceutical ingredient (API), as opposed to the products themselves. Ibuprofen, naproxen, aspirin, and acetaminophen are some of the over-the-counter drugs that can be used to treat premenstrual syndrome.

The key market growth drivers for this particular category include an increase in the demand for over-the-counter (OTC) items, an increase in awareness about OTC medicines, and an increase in the number of hospital pharmacies, drug stores, retail pharmacies, and internet pharmacies across the globe. In addition, the utilization of over-the-counter (OTC) products is increasing due to the low cost of OTC products and the convenience of availability.

Based on the distribution channel, the global market for premenstrual syndrome treatment is bifurcated into hospital pharmacies, drug stores, retail pharmacies, and online providers.

The drug stores and retail pharmacies segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 3.2% over the forecast period. A drug store or retail pharmacy is a type of business that involves distributing and selling various pharmaceutical products. In addition, pharmacies may sell cosmetics, first-aid supplies, patent medications, over-the-counter drugs, and drugs that do not require a doctor's prescription. In addition, retail pharmacists counsel patients on the appropriate use of over-the-counter (OTC) medications and offer patients information regarding general health. Drug stores and retail pharmacies are the primary revenue generator for the market. This trend is expected to continue during the projection period due to the widespread presence of retail pharmacies worldwide and their convenience.

Recent Developments

• September 2023- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of premenstrual dysphoric disorder (PMDD), including negative mood and physical and behavioral symptoms.
• June 2021- The FDA has approved MYFEMBREE (religieux 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg), the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a treatment duration of up to 24 months, according to Movant Sciences and Pfizer, Inc. Movant and Pfizer would jointly commercialize MYFEMBREE in the U.S. under the terms of their previously announced collaboration. MYFEMBREE is scheduled to be released.